jrnl6420

Publication Venue For

  • Late Mortality after Allogeneic Bone Marrow Transplantation in Childhood for Bone Marrow Failure Syndromes and Severe Aplastic Anemia.  25:749-755. 2019
  • Extended CCR5 Blockade for Graft-versus-Host Disease Prophylaxis Improves Outcomes of Reduced-Intensity Unrelated Donor Hematopoietic Cell Transplantation: A Phase II Clinical Trial..  25:515-521. 2019
  • The Future of Chimeric Antigen Receptor T Cell Therapy for the Treatment of Multiple Myeloma.  25:e73-e75. 2019
  • Late Mortality after Allogeneic Blood or Marrow Transplantation for Inborn Errors of Metabolism: A Report from the Blood or Marrow Transplant Survivor Study-2 (BMTSS-2).  25:328-334. 2019
  • Mobilization of Hematopoietic Progenitor Cells for Autologous Transplantation Using Pegfilgrastim and Plerixafor: Efficacy and Cost Implications.  25:233-238. 2019
  • Comparative Analysis of Calcineurin Inhibitor–Based Methotrexate and Mycophenolate Mofetil–Containing Regimens for Prevention of Graft-versus-Host Disease after Reduced-Intensity Conditioning Allogeneic Transplantation.  25:73-85. 2019
  • Impact of T Cell Dose on Outcome of T Cell-Replete HLA-Matched Allogeneic Peripheral Blood Stem Cell Transplantation 2019
  • Bone Marrow Transplantation after Nonmyeloablative Treosulfan Conditioning Is Curative in a Murine Model of Sickle Cell Disease.  24:1554-1562. 2018
  • Phase 1/2 Trial of Carfilzomib Plus High-Dose Melphalan Preparative Regimen for Salvage Autologous Hematopoietic Cell Transplantation Followed by Maintenance Carfilzomib in Patients with Relapsed/Refractory Multiple Myeloma.  24:1379-1385. 2018
  • Choosing Wisely BMT: American Society for Blood and Marrow Transplantation and Canadian Blood and Marrow Transplant Group's List of 5 Tests and Treatments to Question in Blood and Marrow Transplantation.  24:909-913. 2018
  • Cardiovascular Function in Long-Term Hematopoietic Cell Transplantation Survivors.  23:700-705. 2017
  • National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Subsequent Neoplasms Working Group Report.  23:367-378. 2017
  • Maintenance versus Induction Therapy Choice on Outcomes after Autologous Transplantation for Multiple Myeloma.  23:269-277. 2017
  • National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Research Methodology and Study Design Working Group Report.  23:10-23. 2017
  • Allogeneic Hematopoietic Cell Transplantation as Curative Therapy for Patients with Non-Hodgkin Lymphoma: Increasingly Successful Application to Older Patients.  22:1543-1551. 2016
  • Efficacy of Pharmacokinetics-Directed Busulfan, Cyclophosphamide, and Etoposide Conditioning and Autologous Stem Cell Transplantation for Lymphoma: Comparison of a Multicenter Phase II Study and CIBMTR Outcomes.  22:1197-1205. 2016
  • Late Effects Surveillance Recommendations among Survivors of Childhood Hematopoietic Cell Transplantation: A Children's Oncology Group Report.  22:782-795. 2016
  • Success of an International Learning Health Care System in Hematopoietic Cell Transplantation: The American Society of Blood and Marrow Transplantation Clinical Case Forum.  22:564-570. 2016
  • The Impact of Graft-versus-Host Disease on the Relapse Rate in Patients with Lymphoma Depends on the Histological Subtype and the Intensity of the Conditioning Regimen.  21:1746-1753. 2015
  • Can a female donor for a male recipient decrease the relapse rate for patients with acute myeloid leukemia treated with allogeneic hematopoietic stem cell transplantation?.  21:713-719. 2015
  • Comparison of Outcomes of Allogeneic Transplantation for Chronic Myeloid Leukemia with Cyclophosphamide in Combination with Intravenous Busulfan, Oral Busulfan, or Total Body Irradiation.  21:552-558. 2015
  • Disparities in utilization of autologous hematopoietic cell transplantation for treatment of multiple myeloma.  21:701-706. 2015
  • Fate of Patients with Newly Diagnosed Acute Myeloid Leukemia Who Fail Primary Induction Therapy.  21:559-564. 2015
  • Hematopoietic Stem Cell Transplantation for Multiple Myeloma: Guidelines from the American Society for Blood and Marrow Transplantation.  21:1155-1166. 2015
  • Early Failure of Frontline Rituximab-Containing Chemo-immunotherapy in Diffuse Large B Cell Lymphoma Does Not Predict Futility of Autologous Hematopoietic Cell Transplantation 2014
  • Optimizing autologous stem cell mobilization strategies to improve patient outcomes: Consensus guidelines and recommendations.  20:295-308. 2014
  • Prediction of poor mobilization of autologous CD34+ cells with growth factor in multiple myeloma patients: Implications for risk-stratification.  20:222-228. 2014
  • Central nervous system relapse in adults with acute lymphoblastic leukemia after allogeneic hematopoietic stemcell transplantation.  20:1767-1771. 2014
  • Hematopoietic cell transplant comorbidity index is predictive of survival after autologous hematopoietic cell transplantation in multiple myeloma.  20:402-408.e1. 2014
  • Outcomes of Hematopoietic Cell Transplantation for Diffuse Large B Cell Lymphoma Transformed from Follicular Lymphoma.  20:951-959. 2014
  • Peripheral blood progenitor cell mobilization for autologous and allogeneic hematopoietic cell transplantation: Guidelines from the american society for blood and marrow transplantation.  20:1262-1273. 2014
  • Reduced-Intensity Hematopoietic Cell Transplantation for Patients with Primary Myelofibrosis: A Cohort Analysis from the Center for International Blood and Marrow Transplant Research.  20:89-97. 2014
  • Similar transplantation outcomes for acute myeloid leukemia and myelodysplastic syndrome patients with haploidentical versus 10/10 human leukocyte antigen-matched unrelated and related donors.  20:1975-1981. 2014
  • Unrelated donor allogeneic hematopoietic stem cell transplantation for patients with hemoglobinopathies using a reduced-intensity conditioning regimen and third-party mesenchymal stromal cells.  20:581-586. 2014
  • Trends in utilization and outcomes of autologous transplantation as early therapy for multiple myeloma.  19:1615-1624. 2013
  • Outcomes of Allogeneic Hematopoietic cell transplantation in patients with Dyskeratosis Congenita.  19:1238-1243. 2013
  • Burden of Morbidity in 10+ Year Survivors of Hematopoietic Cell Transplantation: Report from the Bone Marrow Transplantation Survivor Study.  19:1073-1080. 2013
  • Allogeneic th1 cells home to host bone marrow and spleen and mediate ifnγ-dependent aplasia.  19:876-887. 2013
  • Autologous and Allogeneic Transplantation for Burkitt Lymphoma Outcomes and Changes in Utilization: A Report from the Center for International Blood and Marrow Transplant Research.  19:173-179. 2013
  • Second Primary Malignancies after Autologous Hematopoietic Cell Transplantation for Multiple Myeloma.  19:260-265. 2013
  • National Cancer Institute, National Heart, Lung and Blood Institute/Pediatric Blood and Marrow Transplantation Consortium First International Consensus Conference on Late Effects after Pediatric Hematopoietic Cell Transplantation: The Need for Pediatric-Specific Long-Term Follow-up Guidelines.  18:334-347. 2012
  • Randomized Trial of Hydroxychloroquine for Newly Diagnosed Chronic Graft-versus-Host Disease in Children: A Children’s Oncology Group Study.  18:84-91. 2012
  • Subsequent Malignant Neoplasms after Hematopoietic Cell Transplantation.  18. 2012
  • Early and Late Extensive Chronic Graft-versus-Host Disease in Children Is Characterized by Different Th1/Th2 Cytokine Profiles: Findings of the Children's Oncology Group Study ASCT0031.  17:1804-1813. 2011
  • NCI, NHLBI First International Consensus Conference on Late Effects after Pediatric Hematopoietic Cell Transplantation: Etiology and Pathogenesis of Late Effects after HCT Performed in Childhood-Methodologic Challenges.  17:1428-1435. 2011
  • NCI, NHLBI First International Consensus Conference on Late Effects after Pediatric Hematopoietic Cell Transplantation: State of the Science, Future Directions.  17:1424-1427. 2011
  • Efficacy and Safety of Ciprofloxacin for Prophylaxis of Polyomavirus BK Virus-Associated Hemorrhagic Cystitis in Allogeneic Hematopoietic Stem Cell Transplantation Recipients.  17:1176-1181. 2011
  • Comparison of outcomes after transplantation of g-csf-stimulated bone marrow grafts versus bone marrow or peripheral blood grafts from hla-matched sibling donors for patients with severe aplastic anemia.  17:1018-1024. 2011
  • Predictors of Late Cardiovascular Complications in Survivors of Hematopoietic Cell Transplantation.  16:1138-1144. 2010
  • Bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation-an increasingly recognized manifestation of chronic graft-versus-host disease..  16. 2010
  • Long-Term Consequences of Hematopoietic Stem Cell Transplantation: Current State of the Science.  16. 2010
  • Late Effects in Survivors of Hodgkin and Non-Hodgkin Lymphoma Treated with Autologous Hematopoietic Cell Transplantation: A Report from the Bone Marrow Transplant Survivor Study.  13:1153-1159. 2007
  • Second Malignancies after Allogeneic Hematopoietic Cell Transplantation.  13:1121-1134. 2007
  • Altered Toll-Like Receptor 9 Responses in Circulating B Cells at the Onset of Extensive Chronic Graft-versus-Host Disease.  13:386-397. 2007
  • Emerging Targets for Hematopoietic Cell Transplantation (HCT): Genetic Disorders of Hematopoiesis and Immunity.  13:58-63. 2007
  • Improved Outcomes in Intermediate- and High-Risk Aggressive Non-Hodgkin Lymphoma after Autologous Hematopoietic Stem Cell Transplantation Substituting Intravenous for Oral Busulfan in a Busulfan, Cyclophosphamide, and Etoposide Preparative Regimen.  12:770-777. 2006
  • Cardiac manifestations of graft-versus-host disease.  11:773-780. 2005
  • Efficacy of mycophenolate mofetil in the treatment of chronic graft-versus-host disease.  11:307-313. 2005
  • γδ T cells: A new frontier for immunotherapy?.  11:161-168. 2005
  • Reduced-intensity allogeneic stem cell transplantation for patients whose prior autologous stem cell transplantation for hematologic malignancy failed.  9:649-656. 2003
  • Reduced-intensity allogeneic stem cell transplantation for patients whose prior autologous stem cell transplantation for hematologic malignancy failed..  9:649-656. 2003
  • A long-term follow-up report on allogeneic stem cell transplantation for patients with primary refractory acute myelogenous leukemia: Impact of cytogenetic characteristics on transplantation outcome.  9:766-771. 2003
  • A limited sampling strategy for pharmacokinetic directed therapy with intravenous busulfan.  8:619-624. 2002
  • Correction of phenotype in a thalassemia mouse model using a nonmyeloablative marrow transplantation regimen.  8:453-461. 2002
  • Effects of Allogeneic Bone Marrow Transplantation on Recipient Bone Mineral Density: A Prospective Study.  6:344-351. 2000
  • Effects of allogeneic bone marrow transplantation on recipient bone mineral density: A prospective study..  6:344-351. 2000
  • Hydroxychloroquine for the Treatment of Chronic Graft-Versus-Host Disease.  6:327-334. 2000
  • High-dose chemo/radiotherapy and autologous bone marrow or stem cell transplantation for poor-risk advanced-stage Hodgkin's disease during first partial or complete remission.  5:292-298. 1999